Drug General Information
Drug ID	D06BHG
Former ID	DNCL002969
Drug Name	Safotibant
Drug Type	Small molecular drug
Indication	Diabetic macular edema [ICD9: 250, 362.01, 362.07, 362.53, 782.3; ICD10:E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9]		Phase 2	[523403]
Company	Sanofi
Structure		Download 2D MOL 3D MOL
Formula	C25H34N4O5S
PubChem Compound ID	11953367
Target and Pathway
Target(s)	B1 bradykinin receptor	Target Info	Modulator	[551643]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Complement and coagulation cascades
	Inflammatory mediator regulation of TRP channels
	Regulation of actin cytoskeleton
	Pathways in cancer
NetPath Pathway	Leptin Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome	Peptide ligand-binding receptors
	G alpha (q) signalling events
	G alpha (i) signalling events
WikiPathways	Complement and Coagulation Cascades
	ACE Inhibitor Pathway
	Regulation of Actin Cytoskeleton
	GPCRs, Class A Rhodopsin-like
	Vitamin D Receptor Pathway
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 523403	ClinicalTrials.gov (NCT01319487) Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy. U.S. National Institutes of Health.
Ref 551643	The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.